Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11433041 | ACER | Palatable compositions including sodium phenylbutyrate and uses thereof |
Oct, 2036
(12 years from now) | |
US11154521 | ACER | Palatable compositions including sodium phenylbutyrate and uses thereof |
Oct, 2036
(12 years from now) | |
US11202767 | ACER | Methods of treating urea cycle disorders and maple syrup urine disease |
Oct, 2036
(12 years from now) |
Olpruva is owned by Acer.
Olpruva contains Sodium Phenylbutyrate.
Olpruva has a total of 3 drug patents out of which 0 drug patents have expired.
Olpruva was authorised for market use on 22 December, 2022.
Olpruva is available in for suspension;oral dosage forms.
Olpruva can be used as treatment of a urea cycle disorder involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.
The generics of Olpruva are possible to be released after 17 October, 2036.
Drugs and Companies using SODIUM PHENYLBUTYRATE ingredient
Market Authorisation Date: 22 December, 2022
Treatment: Treatment of a urea cycle disorder involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase
Dosage: FOR SUSPENSION;ORAL